SLU-PP-332

SLU-PP-332 is an academic research chemical that activates the estrogen-related receptors and, in mice, switches on some of the genetic programs endurance exercise switches on. It has no completed human clinical trials of any kind — the entire evidence base is rodent and cell work — and it is not approved for human use anywhere.

What SLU-PP-332 is

SLU-PP-332 is a small synthetic molecule created in an academic laboratory as a chemical tool — a compound designed to switch a particular receptor family on so researchers could observe what happens. It was not designed as a medicine, it has not been optimised as one, and it has never been through a human clinical trial.

The receptors it targets are the estrogen-related receptors — ERRα, ERRβ and ERRγ. Despite the name they are not estrogen receptors and they are not activated by estrogen. They are what pharmacologists call orphan nuclear receptors: transcription factors that regulate gene expression, discovered by their structural resemblance to the estrogen receptor rather than by any shared function. SLU-PP-332 is a pan-agonist, activating all three with some preference for ERRα.

It picked up the "exercise mimetic" label — and a large amount of press — because when it was given to mice, it turned on a recognisable slice of the gene program that endurance training turns on, and the animals ran further.

Two things follow from that, and only two. It is a real and interesting piece of pharmacology. And it is a research chemical sold to the public under a disclaimer, with an evidence base that stops entirely at the species boundary.

How it works

Start with the receptors. ERRα, ERRβ and ERRγ sit in the nucleus and control the transcription of genes governing mitochondrial biogenesis, oxidative phosphorylation, fatty-acid oxidation and the Krebs cycle. They are most active in tissues with high energy demand — skeletal muscle, heart, brown fat, kidney. In broad terms they are part of how a cell decides how much oxidative machinery to build.

Now the exercise connection. Endurance training raises a coactivator protein called PGC-1α, often described as the master regulator of mitochondrial biogenesis. PGC-1α does much of its work by partnering with the ERRs — it has little transcriptional activity of its own and depends on receptors like these to direct it to the right genes. So the exercise signal and the ERR signal converge on the same downstream machinery.

SLU-PP-332 enters at the receptor end. Rather than raising PGC-1α through training, it activates the receptors that PGC-1α would have recruited. In mouse muscle and in cell culture this produces increased expression of mitochondrial biogenesis genes, increased fatty-acid oxidation genes, and a shift toward oxidative muscle fibre characteristics — broadly the transcriptional signature of sustained aerobic training.

Two limits are worth stating. First, this mechanism is characterised in mice and cell cultures, not in humans; whether human muscle responds the same way at tolerable exposures is unknown. Second, the molecule itself has been described as having poor drug-like properties — short-lived in the body and unsuited to convenient dosing — which is exactly what you would expect from a laboratory tool rather than a developed drug candidate. Anyone presenting it as a finished product is misrepresenting what it is.

The deeper conceptual limit: switching on a transcriptional program is not the same as producing the adaptation that program normally accompanies. Exercise applies mechanical load, cardiovascular demand, neural drive and metabolic stress simultaneously, across the whole organism. A receptor agonist reproduces one branch of the resulting signal.

What the human evidence actually shows

There are no completed human clinical trials of SLU-PP-332. None. Not phase 1, not a safety study, not a healthy-volunteer pharmacokinetic study. The published evidence base consists of rodent experiments and cell work. This is the single most important fact on the page and it should be stated before anything else, because almost everything written about this compound online implies otherwise.

What the animal work showed. In mouse models, SLU-PP-332 has been reported to increase energy expenditure, improve insulin sensitivity, increase oxidative muscle fibres, raise fat oxidation, extend running endurance, reduce fat mass on an obesogenic diet, and show protective effects in a heart-failure model. Those are consistent and interesting results within their species.

Why that does not carry over automatically. Metabolic and performance findings in mice have a poor record of translating to humans. Rodents differ in metabolic rate, thermoregulation, muscle fibre composition, lifespan and drug handling. The history of metabolic drug development is largely a history of compounds that worked beautifully in mice and then failed in people — on efficacy, on safety, or on both. "Promising in mice" is the starting line, not a result.

There is published work on detecting SLU-PP-332 metabolites for anti-doping purposes. That is sometimes cited as though it were a mark of legitimacy. It is the opposite: analytical chemists develop detection methods for substances they expect to find in athletes' samples. It is evidence that the compound is being used outside research settings, not evidence that it works or that it is safe.

Our overview of the research compounds people are asking about places SLU-PP-332 alongside MOTS-c and explains why "experimental" is the operative word for both.

This is an active research area and the picture may change. If human trials begin and report, that genuinely alters the assessment. Confirm current status with a registered practitioner rather than relying on any single page — including this one.

Regulatory status in Australia

SLU-PP-332 is not on the ARTG and is not TGA-approved for any human therapeutic use. It has not been evaluated for safety, efficacy or quality by any major regulator, anywhere. There is no approved Product Information, no established indication, and no legitimate supply route for human use.

It is an experimental research chemical. Supplying, advertising or importing such a substance for human use sits outside the therapeutic goods framework and can attract TGA enforcement action. The "research use only" label attached to grey-market sales is a disclaimer, not a category that makes human use lawful or sensible — and it does not transfer any quality assurance to the buyer.

Unlike SS-31 or compounded NAD+, this is not a compound with a legitimate compounded prescription pathway in Australia. Compounding requires a prescription written by a registered practitioner for an individual patient, with a compounding pharmacy able to source pharmaceutical-grade material and stand behind the preparation. A research chemical with no human safety data is not a candidate for that pathway. Our explainer on compounded versus TGA-registered medicines sets out the difference between the two lawful routes and everything that sits outside them.

Anti-doping. SLU-PP-332 has no approval for human therapeutic use in any jurisdiction, which places it squarely in the non-approved-substances category prohibited at all times for athletes subject to testing. Detection methods have been published. Any athlete under a testing regime should treat this as a straightforward sanction risk and confirm with their national anti-doping organisation.

Who it is being studied for — and who it is not for

In research terms, ERR agonism is being explored for metabolic disease, heart failure, muscle wasting and conditions where oxidative capacity is impaired. Those are the questions the science is asking, all of it currently preclinical.

The uses being promoted online — endurance gains, fat loss, body recomposition, "exercise in a pill" — have no human data at all supporting them. Not weak data. None.

It is not for anyone. That is a plain statement rather than a rhetorical one: a compound with zero completed human trials has no population in whom a benefit has been demonstrated and no population in whom a safety profile has been established. If you are looking at genuine performance or metabolic goals, the muscle and performance options that have actually been studied in humans are the place to start that conversation with a doctor.

Risks and considerations

The human risk profile is unknown in the fullest sense. No established safe exposure, no characterised side-effect list, no interaction data, no long-term data, no information on effects in pregnancy, in liver or kidney impairment, or alongside common medications. Nobody can tell you what this does to a person over time, because nobody has looked.

Off-target effects are plausible on mechanism. ERRs are active in the heart, skeletal muscle, kidney and metabolic tissues. Chronically pushing a transcription factor family that governs energy metabolism across multiple organs is not a narrowly targeted intervention, and cardiac tissue in particular is not a good place to discover an unexpected effect.

A specific theoretical concern. ERRα activity has been studied in cancer biology, where elevated expression has been associated with less favourable outcomes in certain tumour types. Whether deliberate chronic agonism carries any related risk in humans is unknown. It is not a demonstrated harm and should not be presented as one — but it is precisely the sort of question that phase 1 trials exist to begin answering, and no phase 1 trial has been done.

Product identity and purity. Material bought from research-chemical suppliers is frequently mislabelled, of uncertain purity, or simply not the compound on the vial. There is no independent assurance of identity, dose accuracy or contamination, and no manufacturer accountable if something goes wrong.

Anti-doping and legal consequences are real and additional to the health risks.

What to ask a doctor

• What is my actual goal, and what registered, evidence-based options exist for it?
• Given there are no human trials at all, what would you say the unknowns are?
• Could this affect my heart, my liver or my existing conditions and medications?
• What does the absence of TGA approval mean for me, legally and practically?
• If I compete in tested sport, what are the anti-doping consequences?
• What training, nutrition or registered medical approach would you recommend instead, and what results should I realistically expect?

FAQ

Is SLU-PP-332 approved as a medicine? No. It is not approved by the TGA or any major regulator for human therapeutic use, and it has no completed human clinical trials of any kind.

Have there really been no human trials at all? Correct. The published evidence consists of mouse studies and cell work. Every claim about what it does in people is extrapolation from rodents.

Does it replace exercise? No. In mice it activates part of the transcriptional program that endurance exercise activates. Exercise also delivers cardiovascular, skeletal, neurological, cognitive and psychological benefits through mechanisms this compound does not touch. There is no human evidence it reproduces any of it.

How is it different from MOTS-c? Both attract the "exercise mimetic" label, and both are unapproved, but the mechanisms are unrelated. MOTS-c is a naturally occurring peptide encoded in the mitochondrial genome, proposed to act on cellular energy sensing through AMPK; it at least has an analogue that reached an early-phase human trial. SLU-PP-332 is a wholly synthetic small molecule that activates nuclear receptors to change gene transcription, and it has no human data whatsoever. Grouping them together is a media convenience.

Is it safe to take? Its safety in humans has not been established, and with no clinical data at all there is no informed basis on which to answer the question. The honest position is that nobody knows.

Is it legal to buy it as a "research chemical"? The label describes an intended use that does not include putting it in a person. Supplying, advertising or importing an unapproved substance for human use in Australia sits outside the therapeutic goods framework and can attract enforcement action.

Should I look for a clinic that offers it? A clinic offering an unapproved research chemical with no human trials behind it has answered your question about that clinic. Start with the goal instead. A registered practitioner can investigate what is actually limiting your performance or metabolic health and point you at options with evidence behind them — you can compare doctor-supervised clinics once you know what you are looking for, and take our questions to ask before any protocol with you.